Jefferies Cuts Elanco as Shorts Rebuild Ahead of November Print

Elanco Animal Health heads into its November 6 earnings with a rare split signal: the Street's conviction has fractured in a single session, even as the lending market suggests short sellers are not pressing hard.

The headline event this week was a Jefferies downgrade. The firm cut its rating to Hold from Buy and slashed its price target from $31 to $24, filed on October 20. That move sits against a contrasting backdrop: Goldman Sachs had only just initiated coverage four days earlier with a Buy and a $32 target. The resulting tension is real. The consensus remains Buy, backed by 10 outright buys and 3 outperforms, with the mean target near $30.85, implying around 36% upside to Tuesday's close of $22.70. Bulls point to Q2 beats on revenue, EBITDA, and EPS, a raised full-year guidance range of $5.09bn to $5.14bn in revenue, and a product pipeline anchored by Zenrelia, Quattro, and Befrena with a claimed $2bn-plus peak-sales potential. Bears counter with intense generic pressure, regulatory risk across antibiotic and productivity categories, and the risk that volume growth is not keeping pace with pricing. Morgan Stanley holds at Equal-Weight with a $26 target, consistent with a sideline-leaning view on valuation. EV/EBITDA has drifted to 13.8x, down roughly half a turn over the past month, a modest de-rating that has followed the stock's flat-to-slightly-positive month.

Short positioning tells a more complicated story than the Jefferies move might imply. Short interest climbed sharply through the first half of October, jumping from around 31 million shares in early October to 37 million by mid-month, a 21% rise over 30 days, bringing the figure to 7.5% of the free float. That is a meaningful level, not extreme but well above the point where shorts become consequential to the tape. Yet the borrow market is anything but stressed. Availability is running at 587%, meaning there are roughly six shares available to lend for every one currently borrowed. That compares to the 52-week low availability of 272%, itself not especially tight. Cost to borrow has eased about 7% over the week to just 0.51%, well inside the range it has traded all year. The picture that emerges is one where short sellers rebuilt positions in October but face no pressure from the lending side: borrow is cheap and plentiful, so there is no mechanical squeeze catalyst in the near term. Options reinforce the calmer read. The put/call ratio is at 0.33, more than 1.4 standard deviations below its 20-day average of 0.36, a notably call-heavy skew for a stock down 3.4% on the day. That divergence is worth watching: options traders are positioned constructively even as the stock sold off on the Jefferies news.

Insider behaviour from the past 90 days provides a secondary support signal. Net open-market buying across the period came to roughly $1.37m, driven by a cluster of purchases in August at prices between $21.82 and $23.69. Director Lawrence Kurzius bought 40,000 shares worth just under $936,000 on August 20, and two other directors added smaller amounts the same week. None of those trades were made under a 10b5-1 plan, making them discretionary purchases. The CFO, Robert VanHimbergen, also bought 4,200 shares at $23.08 in August, also outside a pre-arranged plan. The only recent sale on the tape was a small 4,350-share disposal on October 15, executed under a 10b5-1 plan and representing nominal value. The overall insider tone has been constructive, and notably the purchases were made close to current price levels. On the institutional side, Dodge & Cox remains the largest declared holder at 13.5% of shares, FMR and BlackRock each above 9%, with several large holders adding modestly in the September quarter. No 13D activist is on the register; all major holders file as passive 13G holders.

Earnings history is relevant context heading into November 6. The past three prints have all produced negative first-day reactions, with moves of roughly minus 5% and minus 8% on the most recent two occasions. The five-day drift after the August 2026 quarter was minus 13.6%, suggesting that even when the initial move was contained, selling extended through the week. The November print will be the first full quarter where Befrena and the rest of the new product portfolio have a meaningful contribution window, and the bull case rests heavily on whether those launches are tracking ahead of estimates.

With 16 days to results, the key variable is whether the call-heavy options positioning holds or flips as the print approaches, and whether the short interest rebuild of the past month reflects genuine fundamental concern or pre-earnings tactical hedging that could unwind quickly on an in-line quarter.